ReviewDrugs2022
New Topical Therapies in Development for Atopic Dermatitis.
Review in Drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- European S2k Guideline on Chronic PruritusActa dermato-venereologica · 2025Guideline
- Atopic dermatitis and lymphoma risk: a systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- Rademikibart (CBP-201), a next-generation monoclonal antibody targeting human IL-4Rα: Two phase I randomized trials, in healthy individuals and patients with atopic dermatitis.Clinical and translational science · 2023Trial
- Anti-Inflammatory Evaluation of Pyrazino[2,1-Pharmaceuticals (Basel, Switzerland) · 2026Article
- Ruxolitinib Cream As-Needed Monotherapy Demonstrates Sustained Disease and Symptom Control in Patients with Mild to Moderate Atopic Dermatitis: Pooled Analysis from Two Phase 3 Studies.Dermatology and therapy · 2026Article
- Targeting Intracellular Pathways in Atopic Dermatitis with Small Molecule Therapeutics.Current issues in molecular biology · 2025Review
- Anti-Inflammatory Therapies for Atopic Dermatitis: A New Era in Targeted Treatment.Journal of clinical medicine · 2025Review
- Human umbilical cord mesenchymal stem cell therapy for atopic dermatitis through inhibition of neutrophil chemotaxis.Stem cell research & therapy · 2025Article
- IL-24 promotes atopic dermatitis-like inflammation through driving MRSA-induced allergic responses.Protein & cell · 2025Article
- Yin-Hua Li-Shi Decoction Alleviated Atopic Dermatitis Through Regulating Th Cells Balance and Restoring Epithelial Barrier.Journal of inflammation research · 2025Article
- The multifaceted role of phosphodiesterase 4 in tumor: from tumorigenesis to immunotherapy.Frontiers in immunology · 2025Review
- Skin Barrier Repair and Nursing Care in Patients with Atopic Dermatitis: A Narrative Review.International journal of general medicine · 2025Review
- Anti-Atopic Dermatitis Effect of Azalomycin F on 2,4-Dinitrofluorobenzene-Induced Mice and Potential Mechanism.International journal of molecular sciences · 2024Article
- PDE4D: A Multipurpose Pharmacological Target.International journal of molecular sciences · 2024Review
- Aryl hydrocarbon receptor role in chronic inflammatory skin diseases: a narrative review.Postepy dermatologii i alergologii · 2024Review
- Race science without racists: how bigoted paradigms persist in allergy research.Frontiers in public health · 2024Article
- Resveratrol and Its Derivatives in Inflammatory Skin Disorders-Atopic Dermatitis and Psoriasis: A Review.Antioxidants (Basel, Switzerland) · 2023Review
- Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review.Molecules (Basel, Switzerland) · 2023Review
- PDE4 Inhibitors: Profiling Hits through the Multitude of Structural Classes.International journal of molecular sciences · 2023Review
- Difamilast for the treatment of atopic dermatitis.The Journal of international medical research · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis (AD) is a common chronic pruritic inflammatory cutaneous disease. AD is characterized by intense pruritus and enormous clinical heterogeneity. Treatment goals are to improve skin lesions and minimize exacerbations and symptom burden. Currently, topical corticosteroids (TCS) and topical calcineurin inhibitors (TCI) are still considered the main topical therapies in disease treatment. However, despite being very effective, TCS and TCI are not recommended for continuous long-term use, due to potential safety issues. Although research in AD has focused primarily on systemic drugs, more than 20 new topical compounds are under development to treat the disease. This review aims to provide a synthesized summary of the current knowledge about AD topical treatment, echoing existing gaps and coming research trends. The available data seems promising, with some drugs already approved (ruxolitinib being the most recent), and several are in an advanced stage of development and will soon be available for treatment of mild to moderate disease, namely tapinarof, difamilast, and roflumilast. However, longer and larger prospective studies are needed to assess the long-term efficacy and safety of these new compounds and evaluate their benefits over current treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.